Search Clinical Trials
Sponsor Condition of Interest |
---|
Pain and Activity Levels After Orthodontic Separators
Lina Sharab
Dental Malocclusion
The primary aim of this study is to evaluate the reported pain intensity following
placement of Orthodontic separators on healthy volunteers aged 18-49 in relation to their
recorded physical activity level.
Hypothesis 1: The investigators hypothesize that participants with higher daily step
counts1 expand
The primary aim of this study is to evaluate the reported pain intensity following placement of Orthodontic separators on healthy volunteers aged 18-49 in relation to their recorded physical activity level. Hypothesis 1: The investigators hypothesize that participants with higher daily step counts and physical activity levels will report significantly less pain intensity from orthodontic separators than their less active peers following separator placement. Null hypothesis is that participants with higher daily step counts will report the same pain intensity from orthodontic separators than their less active peers following separator placement The secondary aim is to describe the course of pain, at 24 hr intervals, over the next seven days following separator placement. Hypothesis 2: The investigators hypothesize that more physically active participants will report ratings of zero pain intensity faster (sooner) than their less active peers throughout the one week study. Secondary null hypothesis is that more physically active participants will report ratings of zero pain intensity at the same rate as their less active peers throughout the one week study. Type: Interventional Start Date: Jul 2022 |
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
William Stoops
Cocaine Use Disorder
Opioid Use Disorder
The overarching hypotheses of this protocol are that (1) persistent brain glutamate
changes induced by chronic opioid use will exacerbate use of cocaine during opioid
physical dependence and withdrawal and (2) n-acetylcysteine (NAC) will ameliorate
glutamatergic dysregulation, and thus will reduce1 expand
The overarching hypotheses of this protocol are that (1) persistent brain glutamate changes induced by chronic opioid use will exacerbate use of cocaine during opioid physical dependence and withdrawal and (2) n-acetylcysteine (NAC) will ameliorate glutamatergic dysregulation, and thus will reduce both opioid and cocaine demand. These hypotheses will be tested with two specific aims. Specific Aim 1. Determine the reinforcing effects of cocaine in individuals with comorbid opioid and cocaine use disorder with physiological dependence on opioids during NAC maintenance. All subjects will be maintained on oral hydromorphone. They will also be randomly assigned to receive placebo or oral NAC (2.4 g/day), stratified by sex. After dose stabilization, experimental sessions will be conducted in which subjects complete hypothetical cocaine purchase tasks during opioid maintenance and opioid withdrawal. The hypotheses are: 1) cocaine purchasing will be greater during opioid withdrawal and 2) NAC maintenance will attenuate cocaine purchasing across opioid maintenance and withdrawal periods. Specific Aim 2. Evaluate glutamate functionality during periods of opioid maintenance and withdrawal in individuals with comorbid opioid and cocaine use disorder and physiological dependence on opioids during NAC maintenance. Subjects will undergo magnetic resonance spectroscopy to evaluate brain glutamate changes as a function of opioid maintenance/withdrawal state and NAC maintenance. The hypotheses are: 1) glutamate levels will be elevated during opioid withdrawal and 2) NAC maintenance will ameliorate elevated glutamate levels. Type: Interventional Start Date: Dec 2022 |
Muscle Recovery After Critical Illness
Kirby Mayer
ICU Acquired Weakness
Post Intensive Care Unit Syndrome
Muscle Weakness
Critical Illness
The overarching goal of the proposed study is to determine the trajectories of physical
recovery and cellular markers involved with the underlying failure to recover muscle
after critical illness, while exploring which characteristics are associated with
sustained physical disability. This proposal1 expand
The overarching goal of the proposed study is to determine the trajectories of physical recovery and cellular markers involved with the underlying failure to recover muscle after critical illness, while exploring which characteristics are associated with sustained physical disability. This proposal will examine muscle pathophysiology carefully aligned with physical function outcomes in order to longitudinally assess the recovery, or failed recovery, of muscle function in participants after critical illness: 1. to examine the recovery of muscle and physical function in ICU survivors through longitudinal assessments 2. to investigate the underlying cellular markers and mechanisms of muscle recovery in ICU survivors 3. to determine which cellular markers contribute to physical disability in ICU survivors up to 1 year after hospital admission Type: Observational Start Date: Oct 2022 |
Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia
Christoph Hornik
Bronchopulmonary Dysplasia of Newborn
This is a multicenter, randomized, placebo-controlled, sequential dose-escalating,
double-masked, safety study of sildenafil in premature infants (inpatient in Neonatal
Intensive Care Units (NICUs)) with severe bronchopulmonary dysplasia (BPD). expand
This is a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study of sildenafil in premature infants (inpatient in Neonatal Intensive Care Units (NICUs)) with severe bronchopulmonary dysplasia (BPD). Type: Interventional Start Date: May 2021 |
Person-Environment Fit for Persons With Dementia
Elizabeth K Rhodus
Dementia Alzheimers
Alzheimer Disease
This trial will assess feasibility of a non-pharmacological intervention for persons
living with Alzheimer's disease and related dementias (ADRD) to improve behavioral and
psychiatric symptoms of dementia and functional performance.
Using a two-arm, prospective randomized controlled trial, 38 dyad1 expand
This trial will assess feasibility of a non-pharmacological intervention for persons living with Alzheimer's disease and related dementias (ADRD) to improve behavioral and psychiatric symptoms of dementia and functional performance. Using a two-arm, prospective randomized controlled trial, 38 dyads (person with ADRD and caregiver) will complete an 8-week telehealth occupational therapy intervention provided via Zoom with caregivers and persons with dementia or receive an active control with 8 telehealth sessions to discuss publicly available caregiver education with a non-clinical research assistant. Type: Interventional Start Date: Jun 2023 |
Heart of the Family: A Cardiovascular Disease and Type 2 Diabetes Risk Reduction Intervention in Hi1
Gia Mudd
Diabetes Mellitus, Type 2
Cardiovascular Diseases
Rural populations in the U.S. are disproportionately burdened by cardiovascular disease
and type 2 diabetes. Lifestyle modification interventions are needed that support
long-term engagement in risk-reducing health behaviors. This trial will study the effects
of a family-focused, lifestyle interven1 expand
Rural populations in the U.S. are disproportionately burdened by cardiovascular disease and type 2 diabetes. Lifestyle modification interventions are needed that support long-term engagement in risk-reducing health behaviors. This trial will study the effects of a family-focused, lifestyle intervention that is culturally tailored for use with rural Hispanic and non-Hispanic adults. If successful, this community-based intervention has significant potential for broad dissemination to reduce cardiovascular disease and type 2 diabetes health disparities in rural U.S. communities. Type: Interventional Start Date: Sep 2021 |
Human Perception of Odors and Odor Blockers
Tim McClintock
Tobacco Smoking
Smoking Behaviors
The goal of this clinical trial is to determine whether blockers of perception of key
odorants in cigarette smoke have any utility in smoking cessation. The main question it
aims to answer is:
• Can odor blockers be used to suppress perception of the intensity of cigarette smoke in
ways that reduc1 expand
The goal of this clinical trial is to determine whether blockers of perception of key odorants in cigarette smoke have any utility in smoking cessation. The main question it aims to answer is: • Can odor blockers be used to suppress perception of the intensity of cigarette smoke in ways that reduce the ability of the odor of cigarette smoke to increase the urge to smoke. Participants will be asked to smell up to 20 odor samples per session and report on odor pleasantness and desire to smoke. Type: Interventional Start Date: Apr 2024 |
Prospective Evaluation of Pathways for Preterm Birth
John O'Brien, MD
Preterm Birth
Cervix; Pregnancy
This is a single center, prospective cohort study of pregnant patients at high risk for
spontaneous preterm birth: patient's with history of spontaneous preterm birth, patient's
with a short cervix and patient's symptomatic for preterm birth will be included. A
control cohort of nulliparous patient1 expand
This is a single center, prospective cohort study of pregnant patients at high risk for spontaneous preterm birth: patient's with history of spontaneous preterm birth, patient's with a short cervix and patient's symptomatic for preterm birth will be included. A control cohort of nulliparous patients without a short cervix will be recruited to provide baseline data. Plan to enroll 240 patients identified through our ultrasound unit with goal of 60 patients in each group. Type: Observational Start Date: Feb 2022 |
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Massachusetts General Hospital
Cognitive Impairment
Dementia
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is
an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking
and memory problems. Alzheimer's disease and other dementias leave signatures on brain
scans or in the blood called biom1 expand
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) is an NIH-funded consortium dedicated to finding biomarkers involved in age-related thinking and memory problems. Alzheimer's disease and other dementias leave signatures on brain scans or in the blood called biomarkers. The MarkVCID study will measure a panel of candidate biomarkers in 1800 participants and watch them closely to see what they tell us about changes in brain function and risk of memory loss. Age-related problems in thinking and memory represent some of the greatest risks to public health in the US and globally. Diseases that affect small blood vessels in the brain have been shown to be major contributors to these changes. However, research and patient care can be held back by limited biomarkers that identify who should be treated. The MarkVCID Consortium includes 17 US medical centers, a Coordinating Center, an External Advisory Committee, and NIH leadership. Data and biospecimens collected as part of this research study will be stored in a research database and biorepositories, so that researchers can use this information to study brain function. Type: Observational Start Date: Sep 2021 |
Neurobehavioral Mechanisms of Choice in Opioid Use Disorder
Joshua A. Lile, Ph.D.
Opioid Use Disorder
The objective of this protocol is to use probabilistic reinforcement learning choice
tasks and magnetic resonance neuroimaging to demonstrate the impact of problematic opioid
use and opioid withdrawal on dynamic decision-making and reveal the neurobehavioral and
neurobiological processes underlying1 expand
The objective of this protocol is to use probabilistic reinforcement learning choice tasks and magnetic resonance neuroimaging to demonstrate the impact of problematic opioid use and opioid withdrawal on dynamic decision-making and reveal the neurobehavioral and neurobiological processes underlying abnormal task performance. A second objective is to identify an appropriate dose of intravenous remifentanil for subsequent studies in physically dependent individuals with opioid use disorder. Type: Interventional Start Date: Aug 2019 |
STABILITY 2: Anterior Cruciate Ligament Reconstruction +/- Lateral Tenodesis With Patellar vs Quad1
University of Pittsburgh
Anterior Cruciate Ligament Injury
Anterior Cruciate Ligament Reconstruction
Joint Instability
Anterior cruciate ligament (ACL) rupture is one of the most common musculoskeletal
injuries in young individuals, particularly those that are active in sports. Up to 30% of
individuals under the age of 20 years suffer a re-injury to the reconstructed ACL.
Revision ACLR has been associated with dege1 expand
Anterior cruciate ligament (ACL) rupture is one of the most common musculoskeletal injuries in young individuals, particularly those that are active in sports. Up to 30% of individuals under the age of 20 years suffer a re-injury to the reconstructed ACL. Revision ACLR has been associated with degeneration of the articular cartilage and increased rates of meniscal tears, increasing the risk of post-traumatic osteoarthritis (PTOA), additional surgical procedures, reduced physical function and quality of life. As such, strategies to reduce ACLR failure, particularly in young active individuals, are critical to improving short and long-term outcomes after ACL rupture. There is ongoing debate about the optimal graft choice and reconstructive technique. Three autograft options are commonly used, including the bone-patellar-tendon-bone (BPTB), quadriceps tendon (QT) and hamstring tendon (HT). Additionally, a lateral extra-articular tenodesis (LET) may provide greater stability to the ACLR; however, its effect on failure rate is unclear and surgery-induced lateral compartment OA is a concern. To definitively inform the choice of autograft and the need for a LET, this multicenter, international randomized clinical trial will randomly assign 1236 young, active patients at high risk of re-injury to undergo ACLR using BPTB or QT autograft with our without LET. Type: Interventional Start Date: Jul 2020 |
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans1
North American Consortium for Histiocytosis
Langerhans Cell Histiocytosis
The LCH-IV is an international, multicenter, prospective clinical study for pediatric
Langerhans Cell Histiocytosis LCH (age < 18 years). expand
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years). Type: Interventional Start Date: Nov 2016 |
- Previous
- Next